On Monday, Esperion Therapeutics Inc (NASDAQ: ESPR) was 10.71% up from the session before settling in for the closing price of $2.80. A 52-week range for ESPR has been $1.27 – $3.40.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 7.64%. When this article was written, the company’s average yearly earnings per share was at 84.69%. With a float of $195.06 million, this company’s outstanding shares have now reached $195.44 million.
Considering the fact that the conglomerate employs 240 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 81.57%, operating margin of 5.57%, and the pretax margin is -29.37%.
Esperion Therapeutics Inc (ESPR) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Esperion Therapeutics Inc stocks. The insider ownership of Esperion Therapeutics Inc is 1.00%, while institutional ownership is 65.81%. The most recent insider transaction that took place on Nov 19 ’24, was worth 427. In this transaction Chief Commercial Officer of this company sold 197 shares at a rate of $2.17, taking the stock ownership to the 162,355 shares. Before that another transaction happened on Nov 19 ’24, when Company’s Officer proposed sale 197 for $2.17, making the entire transaction worth $427.
Esperion Therapeutics Inc (ESPR) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 84.69% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.90% during the next five years compared to 23.09% growth over the previous five years of trading.
Esperion Therapeutics Inc (NASDAQ: ESPR) Trading Performance Indicators
You can see what Esperion Therapeutics Inc (ESPR) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.37. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.28.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.66, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach 0.34 in one year’s time.
Technical Analysis of Esperion Therapeutics Inc (ESPR)
Compared to the last year’s volume of 6.16 million, its volume of 7.06 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 86.70%. Additionally, its Average True Range was 0.20.
During the past 100 days, Esperion Therapeutics Inc’s (ESPR) raw stochastic average was set at 81.72%, which indicates a significant increase from 76.06% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 88.45% in the past 14 days, which was higher than the 71.46% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.13, while its 200-day Moving Average is $2.22. Nevertheless, the first resistance level for the watch stands at $3.43 in the near term. At $3.77, the stock is likely to face the second major resistance level. The third major resistance level sits at $4.10. If the price goes on to break the first support level at $2.77, it is likely to go to the next support level at $2.44. Now, if the price goes above the second support level, the third support stands at $2.11.
Esperion Therapeutics Inc (NASDAQ: ESPR) Key Stats
There are 197,035K outstanding shares of the company, which has a market capitalization of 673.33 million. As of now, sales total 116,330 K while income totals -209,250 K. Its latest quarter income was 51,630 K while its last quarter net income were -29,520 K.
